ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Fosun Pharma, Bristol-Myers Squibb and Hoffmann-La Roche side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Fosun Pharma×Bristol-Myers Squibb×Hoffmann-La Roche×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Fosun PharmaBristol-Myers SquibbHoffmann-La Roche
studies on the registry2022,1842,744
open to participants now86155114
phase 3 studies under way238295
reach primary completion within a year396776
programswith a study of their own in two years49+18 named only57+9 named only80+25 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseFosun PharmaBristol-Myers SquibbHoffmann-La Roche
Phase 1

Fosun Pharma: 27 of its 49 programs at phase 1

  1. HLX319phase 1
  2. Anti-PD-1/IL-2 Fusion Protein TEV-56278phase 1
  3. Cetuximabphase 1
  4. FXS0260phase 1
  5. FXS0683phase 1

and 22 more — sign in to see them all

55%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%
Phase 2

Fosun Pharma: 9 of its 49 programs at phase 2

  1. BRAF V600E Inhibitor HLX208phase 2
  2. Bcl-2 Inhibitor LOXO-338phase 2
  3. FKC289phase 2
  4. FXR0906phase 2
  5. XH-S003 Capsulephase 2

and 4 more — sign in to see them all

18%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
Phase 3

Fosun Pharma: 13 of its 49 programs at phase 3

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. luvometinibphase 3
  5. dulpatatugphase 3

and 8 more — sign in to see them all

27%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
Approved, new studies00%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Fosun Pharma21 readouts · 3 phase 3

Fosun Pharma, Nov ’26: 2 programs whose next study reaches primary completion

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3 · Nov 22 · NCT06839066
  2. FKC876early phase 1 · Nov 30 · NCT07606937

Fosun Pharma, Dec ’26: 2 programs whose next study reaches primary completion

  1. HLX13phase 3 · Dec 0 · NCT07176650
  2. Bcl-2 Inhibitor LOXO-338phase 2 · Dec 1 · NCT06858618

Fosun Pharma, Jan ’27: 1 program whose next study reaches primary completion

  1. HLX29phase 1 · Jan 31 · NCT07776132

Fosun Pharma, Feb ’27: 1 program whose next study reaches primary completion

  1. FXS5626phase 3 · Feb 28 · NCT07552012

Fosun Pharma, Mar ’27: 2 programs whose next study reaches primary completion

  1. HLX48phase 1 · Mar 0 · NCT07473726
  2. HLX37phase 3 · Mar 30 · NCT07274813

Fosun Pharma, Apr ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. HLX17phase 3 · Apr 9 · NCT06847334
  2. HLX319phase 1 · Apr 23 · NCT07601620
  3. FXS887phase 1 · Apr 28 · NCT07345637
  4. FXS6837phase 3 · Apr 29 · NCT07949799
  5. luvometinibphase 3 · Apr 30 · NCT07004075

Fosun Pharma, May ’27: 1 program whose next study reaches primary completion

  1. HLX15phase 3 · May 25 · NCT07477587

Fosun Pharma, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. dulpatatugphase 3 · Jun 1 · NCT06532006
  2. HLX3902phase 1 · Jun 29 · NCT07533708
  3. Cetuximabphase 1 · Jun 30 · NCT07543471

Fosun Pharma, Jul ’27: 1 program whose next study reaches primary completion

  1. pimurutamabphase 3 · Jul 28 · NCT07358585

Fosun Pharma, Aug ’27: 1 program whose next study reaches primary completion

  1. HLX18phase 1 · Aug 12 · NCT07518043

Fosun Pharma, Sep ’27: 2 programs whose next study reaches primary completion

  1. HLX109phase 1 · Sep 20 · NCT07935941
  2. FXR0906phase 2 · Sep 24 · NCT07766759
·
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Fosun Pharma

New programs 5

  • HLX49phase 1 · first study · Nov 12
  • HLX105phase 1 · first study · Nov 4
  • FXS0260phase 1 · first study · Oct 25
  • HLX109phase 1 · first study · Oct 18
  • FXS4640phase 1 · first study · Sep 23

Reached a new phase 3

  • FXR0906phase 2 · Oct 13
  • HLX37phase 3 · Oct 4 · Carcinoma, Non-Small-Cell Lung
  • FXS5626phase 3 · Sep 17 · Uveitis

Study stopped 0

None

Primary completion later 1

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Where they overlap

Conditions where at least two of them have programs: 42 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionFosun PharmaBristol-Myers SquibbHoffmann-La Roche
Carcinoma, Non-Small-Cell Lungall three · compare here

Fosun Pharma in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. HLX17phase 3
  5. HLX37phase 3

and 6 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

Fosun Pharma in Breast Neoplasms: 6 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. dulpatatugphase 3
  3. HLX87phase 3
  4. hx22phase 3
  5. HLX319phase 1

and 1 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Breast Neoplasms in search

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Fosun Pharma in Neoplasms: 5 programs

  1. anlotinibphase 2
  2. Folfox protocolphase 2
  3. Cetuximabphase 1
  4. HLX05phase 1
  5. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Colorectal Neoplasmsall three · compare here

Fosun Pharma in Colorectal Neoplasms: 5 programs

  1. serplulimabphase 3
  2. BRAF V600E Inhibitor HLX208phase 2
  3. Folfox protocolphase 2
  4. XS-03phase 2
  5. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Colorectal Neoplasms in search

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Multiple Myelomaall three · compare here

Fosun Pharma in Multiple Myeloma: 2 programs

  1. HLX15phase 3
  2. hyaluronidase (human recombinant)phase 1

Their studies: Fosun Pharma’s studies of Multiple Myeloma in search

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Alzheimer Diseaseall three · compare here

Fosun Pharma in Alzheimer Disease: 1 program

  1. GV-971no phase

Their studies: Fosun Pharma’s studies of Alzheimer Disease in search

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Small Cell Lung Carcinomaall three · compare here

Fosun Pharma in Small Cell Lung Carcinoma: 3 programs

  1. serplulimabphase 3
  2. anlotinibphase 2
  3. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Small Cell Lung Carcinoma in search

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Carcinoma, Hepatocellularall three · compare here

Fosun Pharma in Carcinoma, Hepatocellular: 1 program

  1. HLX13phase 3

Their studies: Fosun Pharma’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

Hoffmann-La Roche in Carcinoma, Hepatocellular: 1 program

  1. codrituzumabphase 2

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Hepatocellular in search

Leukemia, Lymphocytic, Chronic, B-Cellall three · compare here

Fosun Pharma in Leukemia, Lymphocytic, Chronic, B-Cell: 1 program

  1. Bcl-2 Inhibitor LOXO-338phase 2

Their studies: Fosun Pharma’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Bristol-Myers Squibb in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Hoffmann-La Roche in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. mosunetuzumabphase 3
  2. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Lymphoma, B-Cellall three · compare here

Fosun Pharma in Lymphoma, B-Cell: 2 programs

  1. FXS0683phase 1
  2. XS-04phase 1

Their studies: Fosun Pharma’s studies of Lymphoma, B-Cell in search

Bristol-Myers Squibb in Lymphoma, B-Cell: 1 program

  1. golcadomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, B-Cell in search

Hoffmann-La Roche in Lymphoma, B-Cell: 3 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3
  3. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Lymphoma, B-Cell in search

Neoplasm Metastasisall three · compare here

Fosun Pharma in Neoplasm Metastasis: 2 programs

  1. serplulimabphase 3
  2. luvometinibphase 3

Their studies: Fosun Pharma’s studies of Neoplasm Metastasis in search

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

Stomach Neoplasmsall three · compare here

Fosun Pharma in Stomach Neoplasms: 3 programs

  1. serplulimabphase 3
  2. dulpatatugphase 3
  3. Folfox protocolphase 2

Their studies: Fosun Pharma’s studies of Stomach Neoplasms in search

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

Show all 42

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Fosun Pharma 25 of 49 · Bristol-Myers Squibb 32 of 57 · Hoffmann-La Roche 39 of 80 programs (41 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Fosun Pharma: 18, Bristol-Myers Squibb: 9, Hoffmann-La Roche: 25).